Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Conditions

• Chronic Plaque Type Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• AIN457 300 mg — DRUG
• ustekinumab 45/90 mg — DRUG
• placebo secukinumab — DRUG
  Placebo

Study Details

This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis

Key Dates

Start date

Feb 26, 2014

Status verified

Jun 2017

Primary completion

Jun 29, 2016

Completion

Jun 29, 2016

Study Design

Enrollment

676 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: AIN457 300 mg
  patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive
• Active Comparator: Ustekinumab
  patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive

Primary Outcome Measure

Percentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16 [ Time Frame: Week 16 ]

Locations (26)

Find similar trials in Birmingham, AL